Emergent secures manufacturing deal for Providence Therapeutics COVID-19 Vaccine Candidate

USA – Emergent BioSolutions and Canadain biotechnology company Providence Therapeutics have entered into a five-year contract development and manufacturing (CDMO) services agreement for a Covid-19 vaccine spanning Emergent’s integrated capabilities. Emergent will produce drug substances for Providence’s vaccine candidate, PTX-COVID19-B, as well as provide services for finished products such as filling the vaccine in vials at its Winnipeg facility in Canada. The baseline agreement signed between Emergent and Providence Therapeutics is valued at approximately US$90 million, covering manufacturing services, studies to support global supply chain activities, as well as facility…

Read More

FDA allows export of certain lots of AstraZeneca vaccine made at Baltimore plant

USA – The U.S. Food and Drug Administration has said certain lots of AstraZeneca’s COVID-19 vaccine manufactured at a problem-plagued Baltimore facility are fit to be shipped outside the United States. The plant, owned by Emergent Biosolutions, was producing vaccines for AstraZeneca and Johnson & Johnson but U.S. health regulators in April halted operations following a discovery that J&J’s vaccine was contaminated with material used in the AstraZeneca shots. “The agency conducted a thorough review of facility records and the results of quality testing performed by the manufacturer and reached…

Read More